Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.67 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.67 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10028665 | 0.84 | CHRNB2 (0.85) | CHRNB2CHRNA4CHRNA7RIPK1KDM4E | |
| SCHEMBL7737898 | 0.83 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNA7RIPK1KDM4E | |
| SCHEMBL31044635 | 0.80 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7RIPK1KDM4E | |
| SCHEMBL6674571 | 0.80 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7RIPK1KDM4E | |
| SCHEMBL30093157 | 0.80 | CHRNB2 (0.79) | CHRNB2CHRNA4CHRNA7RIPK1KDM4E | |
| SCHEMBL6826606 | 0.79 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA7RIPK1KDM4E | |
| SCHEMBL2584302 | 0.78 | PYCR1 (0.66) | KDM4EALDH1A1LMNAUSP2CYP3A4 | |
| SCHEMBL8348697 | 0.77 | CHRNB2 (0.73) | CHRNB2CHRNA4CHRNA7RIPK1KDM4E | |
| SCHEMBL21278464 | 0.77 | CHRNB2 (0.73) | CHRNB2CHRNA4CHRNA7RIPK1KDM4E | |
| SCHEMBL6132943 | 0.77 | CHRNB2 (0.73) | CHRNB2CHRNA4CHRNA7RIPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1365755-B1 | USE OF PYRIMIDINE NUCLEOSIDES AND/OR THE PRODRUGS THEREOF FOR COMBATING THE SIDE-EFFECTS OF HAART (HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY) AND OTHER ANTI-VIRAL THERAPIES | PHARMA NORD APS (DK) | 2008-10-22 | — | — | EP | disclosed |
| US-6992072-B2 | Combating side-effects | PHARMA NORD APS (DK) | 2006-01-31 | — | — | US | disclosed |
| US-20040138157-A1 | Combating side-effects | PHARMA NORD APS (DK) | 2004-07-15 | — | — | US | disclosed |
| EP-0594540-B1 | Antiretroviral acyl compounds | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| US-5670497-A | RETROVIRAL PROTEASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1997-09-23 | — | — | US | disclosed |
| EP-0708760-A1 | CYCLIC HYDRAZINE COMPOUNDS | Novartis AG (CH) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002582-A1 | CYCLIC HYDRAZINE COMPOUNDS | CIBA-GEIGY AG (CH) | 1995-01-26 | — | — | WO | disclosed |
| EP-0594540-A1 | Antiretroviral acyl compounds | CIBA-GEIGY AG (CH) | 1994-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138157-A1 | Combating side-effects | POLRMT, TK2, POLM | CHRNB2 4689/4885CHRNA4 4782/4885CHRNA7 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.